IMMUNO-COV™ – The Test for Antibodies that Block SARS-CoV-2 Infection Read More

November 12, 2021

Leveraging Virus Power To Beat Cancer With Vyriad

Vyriad is developing the next generation of targeted cancer therapies using engineered viruses that selectively attack cancer cells and ignite robust immune responses to prevent cancer recurrence. I sat down for a fascinating conversation with Stephen Russell, Co-founder and CEO of Vyriad, to hear about this incredible technology and its potential to transform oncology treatment forever.

Media Inquiries

For inquiries, please contact mediarelations@vyriad.com